{"id":"W4312139428","doi":"10.1136/ijgc-2022-igcs.16","title":"O014/#415 Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Adverse effect; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007871894,0.000769983,0.001375936,0.0002603669,0.0003009757,0.0008154523,0.0005013265,0.0009953784,0.004836455],"category_scores_gemma":[0.0005601982,0.0003395472,0.001313369,0.0002378277,0.0005428324,0.000608291,0.0002197067,0.002112515,0.0008580462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007308811,"about_ca_system_score_gemma":0.001029483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001376841,"about_ca_topic_score_gemma":0.004893366,"domain_scores_codex":[0.9997666,0.00009399078,0.00001034073,0.00004248423,0.00002588738,0.00006071013],"domain_scores_gemma":[0.9996983,0.00005006961,0.00004466167,0.00002883609,0.00001663436,0.0001614814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8243029,0.02039829,0.004919647,0.001009123,0.002905426,0.0002210016,0.0001958003,0.001797571,0.01777101,0.0006503125,0.005918901,0.1199101],"study_design_scores_gemma":[0.8137754,0.1650809,0.01298732,0.00006676515,0.001027526,0.0002052667,0.00008560102,0.0009724597,0.001176402,0.000343651,0.004248903,0.00002971123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914932,0.002322083,0.000228337,0.0006289674,0.000147365,0.0007554403,0.000858945,0.00005757469,0.003508145],"genre_scores_gemma":[0.9867809,0.001922848,0.0008692864,0.001529403,0.0001526683,0.0007844388,0.002221082,0.00002206813,0.005717197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004836455,"threshold_uncertainty_score":0.01617962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04543722970944045,"score_gpt":0.3907274243883293,"score_spread":0.3452901946788888,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}